MD Anderson Researchers To Assess VolitionRx’s NuQ® Assay In Anaplastic Prostate Cancer Diagnosis

MD Anderson Researchers To Assess VolitionRx’s NuQ® Assay In Anaplastic Prostate Cancer Diagnosis
shutterstock_83348491VolitionRx Limited, a life sciences company developing blood-based diagnostic tests for different types of cancer, has announced a collaboration study with the University of Texas MD Anderson Cancer Center's Department of Genitourinary Medical Oncology. MD Anderson researchers will use VolitionRx’s NuQ® assay to distinguish anaplastic prostate cancer, an aggressive form of prostate cancer, from castration-resistant prostate cancer (CRPC). Anaplastic prostate cancers represent 20-30% of all lethal prostate cancers, and are defined as a subset similar to small cell prostate carcinomas, usually not detected during the initial diagnosis but appearing during the castration-resistant progression of the disease. This subtype of prostate cancer is usually linked to an increased aggressiveness and resistance to common prostate cancer treatments, usually requiring early rounds of chemotherapy. For these reasons, the necessity of an objective and efficient non-invasive molecular marker that could allow early identification of anaplastic prostate carcinomas is crucial. The assay that will be assessed by MD Anderson Researchers, NuQ®, is based on VolitionRx’s proprietary Nucleosomics® tech
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *